Abstract:Abstract Vascular endothelial growth inhibitor (VEGI, also known as TNFSF15) is an anti-angiogenic cytokine found to be associated with tumour-related vasculature in certain maligancies. Three isoforms, VEGI 251, VEGI192, and VEGI174, have been identified, all sharing a common extracellular domain of 151 C-terminal amino acid sequence critical for biological activity of all three isoforms. Previous studies showed tumor inhibitory effect of truncated recombinant VEGI proteins in breast and colorectal cancer xenograft models, however, the antitumor activity of the full length VEGI molecules have not been well characterized in other malignancies, including kidney neoplasm. The objective of the present study was set to evaluate biological impact of forced expression of full length VEGI-174 in a renal cell carcinoma (RCC) cell line, 786-O, and in 786-O derived xenograft models. We found that Increased VEGI-174 expression in 786-O cells did not affect cell growth and apoptosis in vitro, but did reduce cell adhesion and the ability of endothelial cells to form capillary-like structures in co-culture. Subcutaneous xenograft models were successfully established using the 786-O RCC cells with or without forced expression of VEGI-174. Significantly reduced tumor volume, accompanied by reduced tumor microvessel density and decreased Ki67 and VEGFR2 expression, was observed in animals injected with VEGI-174 transfected 786-O cells compared to those in the control groups. Our results demonstrated that increased expression of full length VEGI-174 in RCC 786-O cells resulted in significant reduction in tumor volume most likely via angiogenic inhibition rather than on tumor growth per se. Despite the lack of antitumor effect of full length VEGI174 in some xenograft tumor models in other studies, our results suggest that antitumor effect of the full length VEGI-174 may be cancer type specific, and VEGI-174 may still be a valuable candidate toward angiogenesis based cancer therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1356. doi:1538-7445.AM2012-1356

Vascular Endothelial Growth Inhibitor in Human Cancer (Review)

Inhibition of Angiogenesis and Breast Cancer Xenograft Tumor Growth by Vegi, A Novel Cytokine of the Tnf Superfamily

Cloning, Expression and Biological Activity of Vegi(151), A Novel Vascular Endothelial Cell Growth Inhibitor

The Differential Expression of Vascular Endothelial Growth Inhibitor Isoforms, VEGI251, VEGI174 and VEGI192 in Human Clear-cell Renal Cell Carcinoma

Defining Civil Defense in the Information Age

Abstract 1356: Vascular Endothelial Growth Inhibitor - Potential Role in Targeted Therapy in Kidney Neoplasma Via Angiogenic Inhibition

Endocrine Glands-Derived-vascular Endothelial Growth Factor and Tumor

Protein of Vascular Endothelial Growth Inhibitor 174 Inhibits Epithelial-Mesenchymal Transition in Renal Cell Carcinoma in Vivo.

Anti-angiogenic Active Immunotherapy: a New Approach to Cancer Treatment

Vascular Endothelial Growth Inhibitor, Expression in Human Prostate Cancer Tissue and the Impact on Adhesion and Migration of Prostate Cancer Cells in Vitro

Suppression of Renal Cell Carcinoma Growth in Vivo by Forced Expression of Vascular Endothelial Growth Inhibitor.

Expression of Vascular Endothelial Growth Inhibitor (VEGI) in Human Urothelial Cancer of the Bladder and Its Effects on the Adhesion and Migration of Bladder Cancer Cells in Vitro.

Clinical applications of VEGF-trap (aflibercept) in cancer treatment.

Research Advance in Vascular Endothelial Growth Factor and Anti-Tumor

Vascular Endothelial Growth Inhibitor 174 is a Negative Regulator of Aggressiveness and Microvascular Density in Human Clear Cell Renal Cell Carcinoma.

Vascular Endothelial Growth Factors and Liver Diseases.

Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy

Effect of N-Terminal Deletion on Biological Activity of Vascular Endothelial Cell Growth Inhibitor

VEGI 174 Protein and Its Functional Domain Peptides Exert Antitumour Effects on Renal Cell Carcinoma

Vascular Endothelial Growth Inhibitor, a Cytokine of the Tumor Necrosis Factor Family, is Associated With Epithelial-Mesenchymal Transition in Renal Cell Carcinoma.

Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies